ClinicalTrials.gg
CompletedNCT04968574Updated Dec 2, 2024

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of taladegib and placebo in Idiopathic Pulmonary Fibrosis, sponsored by Endeavor Biomedicines, Inc.. Completed at 24 sites in 5 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Endeavor Biomedicines, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Idiopathic Pulmonary Fibrosis with a site in Mexico — 4 open to participants now, 9 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Mexico.

Enrollment
26th of 27
41 · median 372
Started
2021
with 2 others
Phase 2
13 of 27
2 open now
Registered
14th of 27
by date
Lead sponsor
2 of 27
Endeavor Biomedicines, Inc.

Among the 27 studies in Idiopathic Pulmonary Fibrosis with a site in Mexico, this one is the 26th largest by enrollment, is one of 3 that started in 2021, is one of 13 in phase 2, and was the 14th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

4 of the 27 studies in Idiopathic Pulmonary Fibrosis with a site in Mexico are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Idiopathic Pulmonary Fibrosis with a site in Mexico, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • hedgehog
  • smoothened
  • pulmonary fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IPF diagnosis based upon American Thoracic Association, Japanese Respiratory Society, European Respiratory Society, Latin American Thoracic Association guidelines within the last 7 years. Diagnosis will be confirmed to be consistent with IPF by centrally read high resolution computed tomography (HRCT).
  • Ability to successfully perform lung function tests.
  • Subjects are willing to remain on study treatment for the duration of the study.
  • Subjects have a full understanding of the .

Exclusion criteria

Exclusion Criteria:

  • Evidence of other known causes of interstitial lung disease (ILD) (e.g., domestic, and occupational environmental exposures, connective tissue disease [CTD], and drug toxicity), lung transplant expected within 12 months of screening or evidence of lung disease other than IPF including but not limited to asthma, (COPD), uncontrolled pulmonary hypertension and emphysema where computed tomography (CT)-assessed extent of emphysema is greater than extent of fibrosis.
  • History of , including carcinoma during the preceding 5 years. With the following exceptions:

    1. Prior history of in situ basal or squamous cell skin cancer that was successfully treated with curative therapies.
    2. Subjects with other malignancies if they have been continuously disease free for at least 5 years prior to study start.
    3. Subjects with prostate cancer that are managed by surveillance are also eligible.
  • Current use of supplemental oxygen for any condition unless prior approval is received from the Sponsor.
  • Smoking within 6 months of study start, current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
  • Presence of active infection at study start or confirmed active (HIV), virus (HBV) or virus (HCV).
  • Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
  • Current or previous use (within 30 days prior to study start) of the following:

    1. N-acetylcysteine
    2. endothelin receptor antagonist
    3. riociguat
    4. prostacyclin or prostacyclin analogue
    5. Warfarin for IPF
    6. Cytotoxic agents (e.g., colchicine if used for IPF)
    7. Radiation to the lungs
    8. Pulmonary rehabilitation
    9. agent for IPF
    10. medications (e.g., methotrexate, azathioprine)
    11. Systemic or inhaled glucocorticosteroids
    12. Antifibrotic therapy (e.g., nintedanib, pirfenidone)
  • Regular use of phosphodiesterase type-5 inhibitor, occasional use for erectile dysfunction will be allowed.
  • Use of drugs that are known moderate or stronger inhibitors or inducers within 12 days prior to study start.
  • Males and females of who are sexually active and unwilling to use for the duration of the study and for 3 months after their final dose.
  • Females that are pregnant or nursing.
  • Females and males that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final study dose.
  • Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final study dose.
  • Subjects with a history of a severe allergic reaction or anaphylactic reaction or known to any component of ENV-101.
  • Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study investigative site or the study Sponsor.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    ENV-101

    taladegib, 200 mg tablet, once daily for 12 weeks

    Drug: taladegib

  • Placebo comparator
    placebo

    placebo, tablet, once daily for 12 weeks

    Drug: placebo

Interventions

  • hedgehog pathway inhibitor dosed once daily

  • Drugplacebo

    identical tablets to the experimental arm with no active ingredient

06

What researchers measure

Primary outcomes

  1. Change from baseline in frequency of adverse events (AEs)

    An AE is any untoward medical occurrence in a study subject administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment under investigation. Frequency of a given AE is determined by dividing the total number of that AE observed during the study by the total number of subjects in the study.

    Time frame: Baseline to Week 18

  2. Change from baseline in severity of AEs

    Severity of AEs are categorized as mild, moderate or severe as described below: * Mild - Events require minimal or no treatment and do not interfere with the subject's daily activities. * Moderate - Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some interference with functioning. * Severe - Events interrupt a subject's usual daily activity and may require systemic drug therapy or other treatment. Severe events are usually potentially life-threatening or incapacitating.

    Time frame: Baseline to Week 18

  3. Change from baseline in vital sign measurements - pulse

    Comparison of a subject's pulse rate at the beginning of the study to that subject's pulse rate at the completion of the study.

    Time frame: Baseline to Week 18

  4. Change from baseline in vital sign measurements - blood pressure

    Comparison of a subject's blood pressure at the beginning of the study to that subject's blood pressure at the completion of the study.

    Time frame: Baseline to Week 18

  5. Change from baseline in vital sign measurements - respiration rate

    Comparison of a subject's respiration rate (number of breaths taken per minute while at rest) at the beginning of the study to that subject's respiration rate at the completion of the study.

    Time frame: Baseline to Week 18

  6. Change from baseline in vital sign measurements - temperature

    Comparison of a subject's body temperature at the beginning of the study to that subject's body temperature at the completion of the study.

    Time frame: Baseline to Week 18

  7. Change from baseline in blood oxygen saturation level

    Comparison of a subject's blood oxygen saturation level (measured at rest using a pulse oximeter) at the beginning of the study to that subject's blood oxygen saturation level at the completion of the study.

    Time frame: Baseline to Week 18

  8. Incidence of clinical laboratory abnormalities

    Assessment of the clinical laboratory measurements (chemistry, hematology, urinalysis parameters) that are above or below the laboratory normal ranges. Incidence of clinical laboratory abnormalities is determined by dividing the total number of clinical laboratory abnormalities by the total number of subjects in the study.

    Time frame: Baseline to Week 18

  9. Severity of clinical laboratory abnormalities

    Assessment of the severity (defined as either clinically significant or not clinically significant) for the clinical laboratory abnormalities observed during the study.

    Time frame: Baseline to Week 18

  10. Number of hospitalizations

    Assessment of the number of hospitalizations for any reason observed among all subjects from the beginning of the study to the completion of the study.

    Time frame: Baseline to Week 18

Secondary outcomes

  1. Change from baseline of FVC (forced vital capacity)

    FVC is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured during a spirometry test.

    Time frame: Baseline and Week 12

  2. Change from baseline of DLCO (diffusing capacity of the lungs for carbon monoxide)

    DLCO is a measurement of the ease of transfer for carbon monoxide molecules from alveolar gas to the hemoglobin of the red blood cells in the pulmonary circulation.

    Time frame: Baseline and Week 12

  3. Change from baseline of patient reported outcomes by the University of California-San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)

    The UCSD SOBQ consists of 24 questions (21 assess severity of shortness of breath during specific activities of daily living; 3 additional items ask about limitations due to: shortness of breath, fear of harm from overexertion and fear of shortness of breath). Each question has a 6-point scale (0 = "not at all" to 5 = "maximal or unable to do because of breathlessness"), resulting in a total score ranging from 0 to 120 (a higher score represents a worse outcome).

    Time frame: Baseline and Week 12

Other outcomes

  1. Change from baseline of FVC

    Time frame: Baseline and Week 6

  2. Change from baseline of FVC

    Time frame: Baseline and Week 18

  3. Change from baseline of DLCO

    Time frame: Baseline and Week 6

  4. Change from baseline of DLCO

    Time frame: Baseline and Week 18

  5. Change from baseline of patient reported outcomes by the UCSD SOBQ

    Time frame: Baseline and Week 6

  6. Change from baseline of patient reported outcomes by the UCSD SOBQ

    Time frame: Baseline and Week 18

07

Study locations

24 sites
  • Research Site
    Liverpool, New South Wales 1871, Australia
  • Research Site
    Benowa, Queensland 4217, Australia
  • Research Site
    Box Hill, Victoria 3128, Australia
  • Research Site
    Clayton, Victoria 3168, Australia
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site (Namdong District)
    Incheon, Korea, Republic of
  • Research Site (Bundang District)
    Seongnam, Korea, Republic of
  • Research Site (Gangnam District)
    Seoul, Korea, Republic of
  • Research Site (Seongbuk District)
    Seoul, Korea, Republic of
  • Research Site (Songpa District)
    Seoul, Korea, Republic of
  • Research Site
    Batu Caves, 68100, Malaysia
  • Research Site
    Kota Bharu, 15200, Malaysia
  • Research Site
    Kuala Lumpur, 53000, Malaysia
  • Research Sire
    Kuala Lumpur, 56000, Malaysia
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Monterrey, Nuevo Leon 64060, Mexico
  • Research Site
    Monterrey, Nuevo Leon 64718, Mexico
  • Research Site
    San Nicolás De Los Garza, Nuevo Leon 66465, Mexico
  • Research Site
    Chihuahua, 31203, Mexico
  • Research Site
    Mexico City, 03100, Mexico
  • Research Site
    Mexico City, 14080, Mexico
  • Research Site
    Oaxaca, 68000, Mexico
  • Research Site
    Puebla, 72180, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Nov 2023, 27 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 27 months is close to that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2021
First posted
Jul 20, 2021
StartActual
Aug 26, 2021
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Results delay requested
Nov 27, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04968574
Lead sponsor
Endeavor Biomedicines, Inc.
Responsible party
Sponsor
First posted
Jul 20, 2021
Start date
Aug 26, 2021
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Last update
Dec 2, 2024

Study contacts

John Huetsch, M.D.
study director · Endeavor Biomedicines

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion